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Abstract
Background: Our aim was to determine if hyponatremia, defined as serum sodium level 
< 135 mmol/L, is a predictor of worse outcome in a cohort of real-world patients with heart 
failure (HF).
Methods: We used data of the National registry of HF (RICA) from Spain, an ongoing mul-
ticenter, prospective cohort study. The patients were assigned to two groups regarding sodium 
levels. Primary end-point was first all-cause readmission, or death by any cause. Secondary 
end-points were the number of days hospitalized, and the presence of complications.
Results: We identified 973 patients, 147 (15.11%) with hyponatremia. The median age of 
patients enrolled was 77.25 ± 8.79 years-old, the global comorbidity measured by Charlson 
comorbidity index (CCI) was upper 3 points and preserved ejection fraction was present in 
67.1% of them. Clinical complications during admission were significantly higher in the 
patients with hyponatremia (35.41%, p < 0.001) and this remained as significant predictor 
after logistic regression adjustment (OR 1.08, p < 0.01). Also mortality and readmissions 
were more frequent in patients with hyponatremia (20.69% and 22.41%, respectively) but after 
Cox regression adjustment hyponatremia in our cohort was not associated with increase in 
90-day all-cause mortality and readmissions, and only CCI remained significant for primary 
end-point (HR 1.08, p < 0.001).
Conclusions: Hyponatremia is an independent predictor of complications during hospitaliza-
tion in our real-world cohort, but was not associated with 90 days mortality or readmissions. 
Global comorbidity, however, played an important role, and could influence the mortality and 
readmissions of our patients. (Cardiol J 2013; 20, 5: 506–512)
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Introduction
Hyponatremia defined as serum sodium level 
< 135 mmol/L, is a common electrolyte abnormali-
ty in hospitalized patients, and it is associated with 
increasing morbidity and mortality.
Patients with heart failure (HF) are not exempt 
from this association, and 19% to 25% of patients 
with acute decompensated heart failure (ADHF) 
have hyponatremia [1, 2].
In the last few years, several studies reported 
that plasma sodium level on admission is an inde-
pendent predictor of increased rates of rehospita-
lization and mortality in patients hospitalized for 
HF [3–5],  it is also associated with longer length 
of stay [1], and is more likely to require dialysis 
and inotropic agents [1]. However, the question 
whether there is a cause-and-effect mechanism 
remains unclear.
In most of these studies, patients were admit-
ted in Cardiology wards. They had several differen-
ces with the patients usually admitted to internal 
medicine wards regarding the age, comorbidity and 
etiology of HF. In addition, most of these studies 
had not been designed to investigate exclusively 
the predictive value of hyponatremia in the clinical 
course of patients with HF.
Our aim was to determine the relationship be-
tween hyponatremia and prognosis in patients with 
HF admitted to internal medicine departments.
Methods
Patients were recruited through the National 
Registry of Heart Failure (RICA), supported by 
the Heart Failure-Working Group of the Spanish 
Society of Internal Medicine (SEMI-IC). The RICA 
Registry is an ongoing multicenter, prospective, 
cohort study that has been described elsewhere 
[6, 7]. This registry included consecutive and uni-
que patients with HF according to the criteria of the 
European Society of Cardiology [8]. The patients 
were exclusively admitted to internal medicine 
wards of 52 public and private hospitals in Spain 
between March 2008 and October 2011. They were 
included on discharge after an ADHF, and then they 
were followed-up for 1 year, with visits at 3 and 
12 months after inclusion.
The study protocol was approved by the Ethics 
Committee of the University Hospital “Reina So-
fia”, Córdoba (Spain), and all patients provided their 
informed consent. Data were collected through 
a web site (https://www.registrorica.org), which 
contained the database, accessed with a personal 
password. Confidentiality was preserved since no 
personal data was stored, except date of birth and 
name initials to avoid data duplication.
Data collection and follow-up
Upon admission we obtained a comprehensive 
medical history and undertook a detailed physi-
cal examination. We assessed comorbidity with 
Charlson index (CCI) [9], basal functional status 
with Barthel index [10], and cognitive status with 
Pfeiffer questionnaire [11]. We also registered 
data of laboratory evaluation including levels of 
creatinine, urea, glucose, sodium, potassium and 
hemoglobin, complications during admission and 
prescriptions at discharge. We excluded patients 
whose laboratory data were not fully completed, 
patients without echocardiographic examination 
and patients who died during hospitalization. All 
patients in this study were followed for 90 days 
after discharge. For rehospitalized patients or those 
who died during follow-up, data on the cause of 
readmission or death were obtained.
Hyponatremia was defined as levels of serum 
sodium under 135 mmol/L and all patients were 
hypervolemic. Each patient was assigned to one 
of the following two groups: hyponatremia if so-
dium < 135 mmol/L, and normonatremia if sodium 
≥ 135 mmol/L. The patients with levels of serum 
sodium ≥ 148 mmol/L, were also excluded.
End-points
The primary end-point was either first all-cau-
se readmission, or death by any cause. Secondary 
end-points were the number of days hospitalized, 
and the presence of complications, such as wor-
sening of renal function (defined by elevation of 
creatinine basal levels ≥ 2 mg/dL), hyperpota-
semia (defined by elevation of serum potassium 
≥ 5.5 mg/dL), acute confusional syndrome, urinary 
tract infections, pneumonia, and needing for blood 
transfusion, hemofiltration or needing for either 
inotropic or hypotensive drugs.
Statistical analysis
We compared variables between patients with 
hyponatremia or normal sodium levels, who were 
used as the reference group. We firstly conduc-
ted univariable analysis between the groups. We 
used the c2 test for dichotomous and qualitative 
variables, and the Kruskal-Wallis test for conti-
nuous variables. We then conducted multivariable 
analysis by Cox regression model for morbidity 
and mortality outcome variables, adjusted to sig-
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nificant variables in univariable analysis (outcome 
were defined as the time to the event or at least 
90 days of follow-up if an event did not occur). 
A logistic regression model was used to analyze 
the complications at admission adjusted to va-
riables with significant differences in univariable 
analysis.
Cumulative event curves were estimated by 
Kaplan-Meier method and compared by Cox re-
gression test. Differences and correlations were 
considered significant at p < 0.05.
Results
We enrolled 973 patients (46.25% men) ad-
mitted for ADHF with a mean of 77.2 ± 8.8 years. 
Hyponatremia was present in 147 (15.1%) patients. 
Nobody had severe hyponatremia (serum sodium 
£ 120 mmol/L). Baseline characteristics of the 
patients are showed in Table 1. The patients with 
hyponatremia had significantly more global comor-
bidity measured by CCI and more frequency of 
renal failure. Levels of glucose, urea, creatinine, 
Table 1. Baseline characteristics of the patients with or without hyponatremia. Values are given as 
number (%) or as median (interquartile range).
Variable Na < 135 mmol/L Na ≥ 135 mmol/L P
N 147 826
Age [years] 78 (12%) 79 (10%) 0.85
Gender (men) 64 (43.54%) 386 (46.73%) 0.47
Hypertension 125 (85.03%) 688 (83.29%) 0.59
Diabetes 74 (50.34%) 339 (43.46%) 0.12
Alcohol 22 (14.97%) 197 (12.83%) 0.15
Smoking 14 (9.52%) 67 (8.11%) 0.56
Dyslipidemia 72 (48.98%) 362 (43.83%) 0.24
Myocardial infarction 37 (25.17%) 165 (19.98%) 0.57
Cerebrovascular disease 19 (12.93%) 107 (12.95%) 0.94
Peripheral vascular disease 16 (10.88%) 109 (13.20%) 0.87
Renal disease 71 (48.3%) 281 (34.02%) 0.005
CCI 4 (4%) 3 (4%) 0.001
Barthel index 90 (30%) 95 (25%) 0.17
Pfeiffer index 1 (3%) 1 (3%) 0.16
CHF severity (NYHA functional class)
I 9 (6.12%) 77 (9.32%) 0.42
II 67 (45.58%) 396 (47.94%) 0.42
III 61 (41.5%) 711 (37.65%) 0.42
IV 10 (6.8%) 42 (5.08%) 0.42
Heart rate [bpm] 82 (28%) 86 (31%) 0.21
SBP [mm Hg] 130 (42%) 140 (39%) 0.002
DBP [mm Hg] 72 (18%) 78 (24%) 0.002
Creatinine [mg/dL] 1.32 (0.8%) 1.14 (0.6%) 0.004
Hemoglobin [g/dL] 12.1 (2.4%) 12.1 (3%) 0.08
Glucose [mg/dL] 122 (87%) 113 (56%) 0.009
Urea [mg/dL] 66 (60%) 57 (36%) 0.006
Potassium [mmol/L] 4.4 (0.8%) 4.2 (0.7%) 0.006
EF 50 (20%) 53 (23%) 0.19
Preserved EF 99 (67.35%) 553 (66.95%) 0.92
Clinical complications during admission 53 (36.05%) 186 (22.52%) 0.0004
Pleural effussion 68 (46.26%) 289 (34.99%) 0.009
Atrial flutter/fibrillation 84 (57.14%) 435 (52.66%) 0.26
Pro-BNP [60/303] 3879.5 (8322.5%) 3043 (5652.0%) 0.56
CCI — Charlson comorbidity index; CHF — chronic heart failure severity; SBP — systolic blood pressure; DBP — diastolic blood pressure; 
EF — ejection fraction; Pro-BNP — B type natriuretic peptide; obtained in 60 patients with hyponatremia and 303 patients with normal 
serum sodium
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and potassium were significantly higher in the 
group of hyponatremia, and blood pressure was 
significantly lower.
The patients (both normonatremics and hy-
ponatremics) taking either angiotensin converting 
enzyme inhibitors or angiotensin receptor blokers 
were 76.7%, loops diuretics 81.2%, thiazides 10.9% 
and 53.4% were receiving beta-blockers. There 
were no differences between the two groups of 
patients.
Clinical complications and pleural effusion 
during admission were higher in the group of 
patients with hyponatremia (35.41%, p < 0.001). 
Findings are shown in Table 2. This group suffe-
red more worsening of basal renal function, more 
hyperpotasemia, more need for vasoactive and 
hypotensive drugs, more need for hemofiltration, 
more frequency of acute confusional status, and 
more frequency of urinary infections than the group 
with normal sodium. Hyponatremia (OR 1.63, 
p < 0.01) and CCI (OR 1.08, p < 0.01) remained 
as significant independent predictors when ente-
red into the adjusted logistic regression model as 
shown in Table 3.
From the initial sample, 763 patients, 647 
with normal sodium and 116 with hyponatremia 
completed the follow-up (11 patients were lost 
and 199 had not arrived to 90-day visit yet). Mor-
tality occurred in 73 (11.4%) patients with normal 
sodium and in 24 (20.7%) with hyponatremia 
(p < 0.006). Readmission was also more frequent in 
patients with hyponatremia (Table 4). However, by 
adjusting the primary end-point through Cox regres-
sion test, hyponatremia was not associated neither 
with mortality nor readmission and only the CCI and 
systolic blood pressure were (OR 1.08, p < 0.001, 
Table 5, Fig. 1).
Discussion 
The main findings that our study showed, were 
that hyponatremia in HF patients was associated 
with more clinical complications during admission, 
but neither with short-term mortality nor its re-
admissions.
In our cohort, hyponatremia was present in 
15.1% of patients with ADHF. This percentage was 
slightly lower than frequencies reported in other 
studies, which ranged between 20% to 25% [1, 12, 
13] possibly because we did not include the patients 
Table 2. Clinical complications in heart failure patients with and without hyponatremia. Values are  
given as number (%) or as median (interquartile range).
Variable Na < 135 mmol/L  
(n = 147)
Na ≥ 135 mmol/L  
(n = 826)
P
Length of stay hospitalized 9 (8%) 7.5 (7%) 0.0005
Total complications 53 (36.05%) 186 (22.52%) 0.0004
Worsening of renal function 22 (14.97%) 68 (8.23%) 0.009
Hyperpotassemia 12 (8.16%) 39 (4.72%) 0.08
Need for vasoactive drugs 9 (6.12%) 22 (2.66%) 0.02
Need for hypotensive drugs 22 (14.97%) 62 (7.51%) 0.003
Need for ultrafiltration 1 (0.68%) 0 (0%) 0.017
Need for blood 6 (4.08%) 31 (3.75%) 0.84
Acute confusional status 20 (13.61%) 46 (5.57%) 0.0004
Pneumonia 3 (2.04%) 12 (1.45%) 0.59
Urinary infection 12 (8.16%) 29 (3.51%) 0.009
Tromboembolic disease 1 (0.68%) 6 (0.73%) 0.95
Table 3. Factors associated with clinical compli-
cations in logistic regression model, adjusted for 
significant variables in univariable analysis.
Variable Odd ratio 95% CI P
SBP 1.00 0.99–1.00 0.97
DBP 1.00 0.99–1.01 0.38
Renal failure 1.03 0.85–1.25 0.74
CCI 1.08 1.01–1.15 0.01
Urea 1.00 0.99–1.00 0.06
Creatinine 1.15 0.86–1.53 0.32
Potassium 1.14 0.89–1.46 0.27
Glucose 1.00 0.99–1.00 0.55
Pleural effusion 1.24 0.91–1.7 0.16
Hyponatremia 1.63 1.10–2.42 0.01
CI — confidence interval; SBP — systolic blood pressure;  
DBP — diastolic blood pressure; CCI — Charlson comorbidity index
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who died during hospitalization. Low serum sodium 
was associated with more clinical complications 
during admission such as acute confusional status, 
worsening of renal function, need for vasoactive 
and hypotensive drugs, and with a higher length 
of stay, similar to previous studies [1], but also 
with more urinary infections. This finding has not 
been not previously reported and may be related 
to a wider use of urinary catheter for more strict 
control of diuresis in hyponatremic patients, how-
ever, the urinary catheter is widely used in patients 
hospitalized for any cause, especially in patients 
with HF, therefore, more studies are necessary 
to confirm it. Mortality and readmissions were 
higher in patients with hyponatremia (20.7% vs. 
11.4% and 22.4% vs. 17.5%, respectively). The 
differences are clinically relevant although there 
was no association in multivariate analysis.
Our sample includes a real-world cohort 
of internal medicine patients with ADHF, and dif 
-fers from others in age (our patients were older 
with a median of 78–79-year-old), comorbiditiy 
(CCI higher than 3 points), and in a raised percen-
Figure 1. Kaplan Meier survival curves regarding plasma 
sodium levels. Adjusted for renal disease, Charlson co-
morbidity index, systolic and diastolic blood pressure, 
creatinine, potassium, glucose and urea. A. The asso-
ciation with primary end-point; B. The association with 
all-causes mortality.
Table 4. Association of serum sodium levels with outcomes. Univariate analysis was performed using 
c2 test and multivariate using Cox regression model adjusted for renal disease, Charlson comorbidity 
index, systolic and diastolic blood pressure, creatinine, potassium, glucose and urea.
Outcome Univariate analysis Multivariate analysis
Na < 135 mmol/L 
(n = 116)
Na ≥ 135 mmol/L 
(n = 647)
HR 95% CI P HR 95% CI P
Readmission 26 (22.41%) 113 (17.47%) 1.36 0.84–2.27 0.2 1.03 0.65–1.64 0.87
Mortality 24 (20.69%) 73 (11.44%) 2.05 1.23–3.41 0.006 1.28 0.78–2.11 0.3
Primary end-point 46 (39.66%) 180 (27.82%) 1.70 1.13–2.56 0.005 1.26 0.89–1.78 0.18
HR — hazard ratio; CI — confidence interval
Table 5. Factors associated with primary end-
-point. Cox regression analysis adjusted to signi-
ficant variables in univariate analysis.
Variable HR 95% CI P
SBP 0.99 0.87–0.99 0.03
DBP 0.99 0.99–1.00 0.87
Renal failure 1.07 0.9–1.27 0.4
CCI 1.08 1.03–1.14 0.001
BUN 1.00 0.99–1.00 0.17
Creatinine 0.93 0.71–1.22 0.62
Glucose 1.00 0.99–1.00 0.56
Hyponatremia 1.13 0.66–1.91 0.64
HR — hazard ratio; CI — confidence interval; SBP — systolic 
blood pressure; DBP — diastolic blood pressure; BUN — blood 
urea nitrogen; CCI — Charlson comorbidity index
tage of patients with non left ventricular systolic 
dimension (67.35% and 66.95% by group). Perhaps 
some of these differences might contribute to the 
higher mortality shown in this study.
Evidence suggests that the patients who have 
HF with preserved ejection fraction, are more 
likely to be older and to be female [14]. Older 
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patients have a higher prevalence of comorbid 
illnesses than their younger counterparts, and in 
the setting of HF, age or sex differences have been 
demonstrated in left ventricular adaptation and au-
tonomic responses, as well as in the clinical course 
and outcomes of the disease [15, 16].
The median age of patients enrolled in pre-
vious trials that researched the relationship be-
tween serum sodium in patients with HF and their 
prognostic was lower [1, 12, 13] and comorbidity 
measured by CCI was not included at all, although 
a recent study shows an increased comorbidity 
among patients with hyponatremia and HF [17]. In 
our sample, comorbidity was significantly higher in 
the patients with hyponatremia and was regarded 
as both significant and independent variable with 
clinical complications during admission and with 
a worse outcome (mortality and readmissions) at 
90 days of follow-up (Table 5).
There are other studies that have shown that 
chronic comorbidities independently increase the 
mortality rates of patients with newly diagnosed 
HF [18] and also in ambulatory HF population [19]. 
In addition, there are other studies that showed 
a relationship between hyponatremia and a higher 
comorbidity measured by CCI [20]. In our study, 
in fact, CCI was higher in the hyponatremic group.
The association between underlying medical 
comorbidities measured by CCI and mortality in 
a variety of patients have been demonstrated in seve - 
ral studies [9, 21, 22], however, there are only few 
of them that use it in the HF population. It could be 
postulated that there is not a true cause-and-effect 
between HF and hyponatremia, but a surrogate 
marker of comorbidity of these patients. Further 
studies will be needed to clarify this aspect.
Finally, it has been shown how systolic blood 
pressure plays a protective role for the primary 
end-point in our sample (Table 5). Low blood 
pressure is often associated with hyponatremia in 
patients with HF [23, 24], and then associated with 
a worse prognosis in these patients [7], which again 
suggests that hyponatremia would be a surrogate 
marker of more severe HF.
Definitely, hyponatremia has shown to be 
a prognostic indicator of increased mortality in 
a determined group of patients with HF, as clinical 
trials were focusing on a relatively small segment 
of the HF population, however, in wider popula-
tion, like ours, with older people who have more 
comorbidity, and more percentage of patients with 
preserved ejection fraction, this question remains 
to be investigated, likewise, future trials with hy-
ponatremic patients and HF should include data of 
comorbidity to validate the results that we have 
obtained in this study.
Limitations of the study
Our present study has several limitations that 
must be considered. First, the number of patients 
included was lower than in other studies. In addi-
tion, all physicians are enrolled in RICA registry 
voluntarily, hence our cohort was obtained from 
patients admitted under the care of a group of 
specially committed physicians, particularly inte-
rested in HF, which could represent a sample bias. 
Finally, only admission serum sodium levels were 
considered, so differentials effects of persistent 
vs. corrected hyponatremia could not be deter-
mined. In addition, admission diuretic dose was 
not collected, consequently, potential association 
between diuretic dose and hyponatremia could not 
be examined.
Conclusions
In conclusion, in this study our real world 
sample has shown that hyponatremia is a predictor 
of complications while admission in HF patients, 
but it has also shown that comorbidity could play 
an important role in the presence or absence of 
hyponatremia and could even influence the 90 days 
mortality or admissions attributed to lower serum 
sodium. Furthermore, the relationship among 
both age and comorbidity and their association to 
survival in HF patients are likely more involved 
than previously described and demand validation 
in other studies that include a wide population.
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